TY - JOUR
T1 - Prolactin and Venous Thrombosis Indications for a Novel Risk Factor?
AU - van Zaane, Bregje
AU - Squizzato, Alessandro
AU - Reuwer, Anne Q.
AU - van Zanten, Anton P.
AU - Twickler, Marcel T. B.
AU - Dekkers, Olaf M.
AU - Cannegieter, Suzanne C.
AU - Büller, Harry R.
AU - Gerdes, Victor E. A.
AU - Brandjes, Dees P. M.
PY - 2011
Y1 - 2011
N2 - Objective-Several acquired risk factors for venous thrombosis (VT) are associated with high prolactin levels. Our goal was to investigate VT risk for different levels of prolactin. Methods and Results-We used data of a case-control study on leg vein thrombosis conducted between September 1999 and August 2006 at the Academic Medical Center, Amsterdam, the Netherlands. Prolactin was assessed in 187 cases (mean age, 57 years; range, 19 to 90) and 374 gender-matched controls (mean age, 57 years; range, 18 to 93). Odds ratios and 95% CI for VT risk were estimated based on several cutoff levels derived from prolactin levels in controls. Odds ratios for VT risk clearly increased with higher prolactin levels. For prolactin levels above the 75th percentile (8 mu g/L), we found a gender-adjusted odds ratio of 1.7 (95% CI 1.0 to 2.7) as compared with levels below the 50th percentile (6 mu g/L). This further increased up to an odds ratio of 4.7 (95% CI 1.8 to 11.8) for prolactin levels above the 97.5th percentile (16 mu g/L). The risk was most pronounced in premenopausal women. Conclusion-Our data suggest that prolactin levels are associated with VT in a dose-dependent fashion. Future studies are needed to evaluate the causality of this relationship. (Arterioscler Thromb Vasc Biol. 2011;31:672-677.)
AB - Objective-Several acquired risk factors for venous thrombosis (VT) are associated with high prolactin levels. Our goal was to investigate VT risk for different levels of prolactin. Methods and Results-We used data of a case-control study on leg vein thrombosis conducted between September 1999 and August 2006 at the Academic Medical Center, Amsterdam, the Netherlands. Prolactin was assessed in 187 cases (mean age, 57 years; range, 19 to 90) and 374 gender-matched controls (mean age, 57 years; range, 18 to 93). Odds ratios and 95% CI for VT risk were estimated based on several cutoff levels derived from prolactin levels in controls. Odds ratios for VT risk clearly increased with higher prolactin levels. For prolactin levels above the 75th percentile (8 mu g/L), we found a gender-adjusted odds ratio of 1.7 (95% CI 1.0 to 2.7) as compared with levels below the 50th percentile (6 mu g/L). This further increased up to an odds ratio of 4.7 (95% CI 1.8 to 11.8) for prolactin levels above the 97.5th percentile (16 mu g/L). The risk was most pronounced in premenopausal women. Conclusion-Our data suggest that prolactin levels are associated with VT in a dose-dependent fashion. Future studies are needed to evaluate the causality of this relationship. (Arterioscler Thromb Vasc Biol. 2011;31:672-677.)
U2 - https://doi.org/10.1161/ATVBAHA.110.209569
DO - https://doi.org/10.1161/ATVBAHA.110.209569
M3 - Article
C2 - 21164080
SN - 1079-5642
VL - 31
SP - 672
EP - 677
JO - Arteriosclerosis, Thrombosis, and Vascular Biology
JF - Arteriosclerosis, Thrombosis, and Vascular Biology
IS - 3
ER -